19076-89-2

Basic information

• Product Name: (4-NITROPHENOXY) ACETIC ACID ETHYL ESTER
• Synonyms: (4-NITROPHENOXY) ACETIC ACID ETHYL ESTER;ethyl 2-(4-nitrophenoxy)acetate
• CAS NO: 19076-89-2
• Molecular Formula: C₁₀H₁₁NO₅
• Molecular Weight: 225.2
• EINECS: 242-883-7
• Mol File: 19076-89-2.mol
• Article Data: 43

Chemical Properties

• Melting Point: 78-80°
• Boiling Point: 349.5°Cat760mmHg
• Flash Point: 158.7°C
• Appearance: /
• Density: 1.263g/cm³
• Vapor Pressure: 4.7E-05mmHg at 25°C
• Refractive Index: 1.53
• CAS DataBase Reference: (4-NITROPHENOXY) ACETIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (4-NITROPHENOXY) ACETIC ACID ETHYL ESTER(19076-89-2)
• EPA Substance Registry System: (4-NITROPHENOXY) ACETIC ACID ETHYL ESTER(19076-89-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 19076-89-2(Hazardous Substances Data)

Usage

General Description

(4-Nitrophenoxy) acetic acid ethyl ester is a chemical compound with the formula C10H9NO5. It is a nitrophenyl ester of ethyl acetic acid, and it is primarily used as an intermediate in the production of other chemicals. (4-NITROPHENOXY) ACETIC ACID ETHYL ESTER has a yellowish appearance and is soluble in organic solvents. It is also known to have a strong odor. Due to its chemical properties, (4-Nitrophenoxy) acetic acid ethyl ester is commonly used in the manufacturing of pharmaceuticals, agrochemicals, and other industrial products. However, it is important to handle this compound with caution, as it may be harmful if ingested or if it comes into contact with the skin or eyes.

InChI:InChI=1/C10H11NO5/c1-2-15-10(12)7-16-9-5-3-8(4-6-9)11(13)14/h3-6H,2,7H2,1H3

Upstream product

• 100-02-7 4-nitro-phenol 
• 105-39-5 chloroacetic acid ethyl ester 
• 64-17-5 ethanol 
• 79-11-8 chloroacetic acid 
• 824-78-2 4-nitrophenol sodium salt 
• 1798-11-4 4-nitrophenoxyacetic acid 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 1159405-63-6 N-[3-{(1H-benzo[d]imidazol-2-ylthio)methyl}-5-mercapto-4H-1,2,4-triazol-4-yl]-2-(4-nitrophenoxy)acetamide 
• 19076-88-1 (4-nitro-phenoxy)-acetic acid-(2-diethylamino-ethylamide) 
• 50508-33-3 1-(morpholin-4-yl)-2-(4-nitrophenoxy)ethanone 

Relevant articles and documents

Synthesis, molecular docking, dynamic simulation and pharmacological characterization of potent multifunctional agent (dual GPR40-PPARγ agonist) for the treatment of experimental type 2 diabetes

The current manuscript describes two molecules that were designed against PPARγ and GPR40 receptors. The preparation of the compounds was carried out following a synthetic route of multiple steps. Then, the mRNA expression levels of PPARγ, GLUT4, and GPR4

Synthesis, in vitro and in silico studies of a PPARγ and GLUT-4 modulator with hypoglycemic effect

Compound {4-[({4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]phenoxy}acetyl)amino]phenoxy}acetic acid (1) was prepared and the in vitro relative expression of PPARγ, GLUT-4 and PPARα, was estimated. Compound 1 showed an increase of 2-fold in the mRNA

Design and synthesis of α-phenoxy-N-sulfonylphenyl acetamides as Trypanosoma brucei Leucyl-tRNA synthetase inhibitors

Human African trypanosomiasis (HAT), caused by the parasitic protozoa Trypanosoma brucei, is one of the fatal diseases in tropical areas and current medicines are insufficient. Thus, development of new drugs for HAT is urgently needed. Leucyl-tRNA synthetase (LeuRS), a recently clinically validated antimicrobial target, is an attractive target for development of antitrypanosomal drugs. In this work, we report a series of α-phenoxy-N-sulfonylphenyl acetamides as T. brucei LeuRS inhibitors. The most potent compound 28g showed an IC50 of 0.70 μM which was 250-fold more potent than the starting hit compound 1. The structure-activity relationship was also discussed. These acetamides provided a new scaffold and lead compounds for the further development of clinically useful antitrypanosomal agents.

The synthesis and evaluation of phenoxyacylhydroxamic acids as potential agents for Helicobacter pylori infections

Two series of ω-phenoxy contained acylhydroxamic acids as novel urease inhibitors were designed and synthesized. Biological activity evaluations revealed that ω-phenoxypropinoylhydroxamic acids were more active than phenoxyacetohydroxamic acids. Out of these compounds, 3-(3,4-dichlorophenoxy)propionylhydroxamic acid c24 showed significant potency against urease in both cell free extract (IC50 = 0.061 ± 0.003 μM) and intact cell (IC50 = 0.89 ± 0.05 μM), being over 450- and 120-fold more potent than the clinically prescribed urease inhibitor AHA, repectively. Non-linear fitting of experimental data (V-[S]) suggested a mixed-type inhibition mechanism and a dual site binding mode of these compounds.